Istradefylline
Nourianz (istradefylline) is a small molecule pharmaceutical. Istradefylline was first approved as Nourianz on 2019-08-27. It is used to treat parkinson disease in the USA. It is known to target adenosine receptor A2b, adenosine receptor A2a, adenosine receptor A1, and adenosine receptor A3.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| nervous system diseases | D009422 |
Trade Name
FDA
EMA
Nourianz
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Istradefylline
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| NOURIANZ | Kyowa Kirin | N-022075 RX | 2019-08-27 | 2 products, RLD, RS |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| nourianz | New Drug Application | 2024-06-12 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| parkinson disease | EFO_0002508 | D010300 | G20 |
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
ISTRADEFYLLINE, NOURIANZ, KYOWA KIRIN | |||
| 2024-08-27 | NCE | ||
HCPCS
No data
Clinical
Clinical Trials
27 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Parkinson disease | D010300 | EFO_0002508 | G20 | 1 | 9 | 11 | 1 | 1 | 22 |
| Tremor | D014202 | HP_0001337 | R25.1 | — | — | — | 1 | — | 1 |
Indications Phases 3
No data
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Restless legs syndrome | D012148 | EFO_0004270 | G25.81 | — | 1 | — | — | — | 1 |
| Psychomotor agitation | D011595 | — | — | — | 1 | — | — | — | 1 |
| Syndrome | D013577 | — | — | — | 1 | — | — | — | 1 |
| Sleep wake disorders | D012893 | — | G47 | — | 1 | — | — | — | 1 |
| Parasomnias | D020447 | — | G47.5 | — | 1 | — | — | — | 1 |
| Movement disorders | D009069 | HP_0100022 | — | — | 1 | — | — | — | 1 |
| Wounds and injuries | D014947 | — | T14.8 | 1 | 1 | — | — | — | 1 |
| Spinal cord injuries | D013119 | EFO_1001919 | — | 1 | 1 | — | — | — | 1 |
| Spinal cord diseases | D013118 | HP_0002196 | G95.9 | 1 | 1 | — | — | — | 1 |
| Cognitive dysfunction | D060825 | HP_0001268 | G31.84 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Substance-related disorders | D019966 | EFO_0003890 | F13 | 1 | — | — | — | — | 1 |
| Liver diseases | D008107 | HP_0002910 | K70-K77 | 1 | — | — | — | — | 1 |
| Hepatic insufficiency | D048550 | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Apathy | D057565 | HP_0000741 | — | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Istradefylline |
| INN | istradefylline |
| Description | Istradefylline is an oxopurine. |
| Classification | Small molecule |
| Drug class | theophylline derivatives |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CCn1c(=O)c2c(nc(/C=C/c3ccc(OC)c(OC)c3)n2C)n(CC)c1=O |
Identifiers
| PDB | — |
| CAS-ID | 155270-99-8 |
| RxCUI | — |
| ChEMBL ID | CHEMBL431770 |
| ChEBI ID | — |
| PubChem CID | 5311037 |
| DrugBank | DB11757 |
| UNII ID | 2GZ0LIK7T4 (ChemIDplus, GSRS) |
Target
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 1,015 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
4,241 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use